Numerous demographic and clinical factors also likely contribute to these mortality and survival disparities, including socioeconomic status, healthcare access, the proportion of hormone receptor-negative (estrogen and progesterone receptor-negative, or ER-PR-) breast cancers, and tumor stage. Here, NR4A1 is linked to breast carcinoma.